Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Lanz

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Neurology|July 15, 2025
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concernThomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Chemistry & Biology|December 17, 2015
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic OpportunitiesEugene L Piatnitski Chekler, Jessica A Pellegrino, Thomas A Lanz, et al.
Journal of Molecular Biology|December 27, 2011
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's diseaseSherry L La Porte, Sangeetha Subbarao Bollini, Thomas A Lanz, et al.
Science Translational Medicine|July 27, 2018
LRRK2 activation in idiopathic Parkinson's diseaseRoberto Di Maio, Eric K Hoffman, Emily M Rocha, et al.
Human Gene Therapy|December 21, 2021
Biodistribution and Tolerability of AAV-PHP.B-CBh-<i>SMN1</i> in Wistar Han Rats and Cynomolgus Macaques Reveal Different Toxicologic ProfilesXavier Palazzi, Ingrid D Pardo, Madhu P Sirivelu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 6, 2010
Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014Thomas A Lanz, Kathleen M Wood, Karl E G Richter, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 22, 2006
Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, et al.
Nature Neuroscience|October 24, 2020
Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophreniaGun-Hoo Park, Haneul Noh, Zhicheng Shao, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuriesStuart Astbury, Edmond Atallah, Jane I Grove, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin InflammationWei Li, Kimberly K Crouse, Jennifer Alley, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Neurology|July 15, 2025
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concernThomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Chemistry & Biology|December 17, 2015
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic OpportunitiesEugene L Piatnitski Chekler, Jessica A Pellegrino, Thomas A Lanz, et al.
Journal of Molecular Biology|December 27, 2011
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's diseaseSherry L La Porte, Sangeetha Subbarao Bollini, Thomas A Lanz, et al.
Science Translational Medicine|July 27, 2018
LRRK2 activation in idiopathic Parkinson's diseaseRoberto Di Maio, Eric K Hoffman, Emily M Rocha, et al.
Human Gene Therapy|December 21, 2021
Biodistribution and Tolerability of AAV-PHP.B-CBh-<i>SMN1</i> in Wistar Han Rats and Cynomolgus Macaques Reveal Different Toxicologic ProfilesXavier Palazzi, Ingrid D Pardo, Madhu P Sirivelu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 6, 2010
Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014Thomas A Lanz, Kathleen M Wood, Karl E G Richter, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 22, 2006
Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, et al.
Nature Neuroscience|October 24, 2020
Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophreniaGun-Hoo Park, Haneul Noh, Zhicheng Shao, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuriesStuart Astbury, Edmond Atallah, Jane I Grove, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin InflammationWei Li, Kimberly K Crouse, Jennifer Alley, et al.
Pageof 5